

Review of: "Hazard Risk Reductions Should Not Be Communicated as Relative Risk Reductions for Death in Cancer Clinical Trials: Intentional or Inadvertent?"

Jolien Tol¹

¹ Jreoen Bosch Hospital

Potential competing interests: No potential competing interests to declare.

Thoroughly written review on presenting and interpreting outcome measures in cervical cancer trials. Very informative basic statistical principles on the differences between hazard ratio, relative risk reduction and absolute risk reduction. For non-cervical cancer specialized medical oncologists, the topic is important, but the trial data are too detailed. The paper could be more to the point, erasing repetitions and picking the most informative trials as an example without trying to be complete.

The figure with absolute difference, RRR, aRR and NNT is confusing as the unit on the Y-axis cannot be uniformal. Consider a different graphical way of displaying these results.

In summary, I would definitely recommend this paper to any medical oncologist interested in clinical trial appraisal.